# nChroma Bio

nChroma Bio is an Asset Manager based in Boston, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Boston, United States
- **Region:** North America
- **Address:** 201 Brookline Avenue, Boston, MA 02215, United States
- **Founded:** 2024
- **Assets under management:** Undisclosed
- **Website:** www.nchromabio.com
- **LinkedIn:** https://www.linkedin.com/company/nchroma-bio

## Regulatory record

- **Reports private funds:** No

## About

nChroma Bio is a biotechnology firm based in Cambridge, United States, established in 2024. It focuses on developing targeted genetic medicine through in vivo delivery, with a primary emphasis on liver therapies such as CRMA-1001 for treating chronic hepatitis B and D via epigenetic approaches. The company has secured $75 million in total funding.

## Sectors

- Genetic Medicines
- Gene Therapy

## People

- Jeffrey Walsh — Chief Executive Officer
- Melissa Bonner — Chief Scientific Officer
- Jenny Marlowe — Chief Development Officer
- Archie Mathura — Senior Vice President, Finance & Operations
- Lisa McGrath — Chief People Officer
- Jeff Marrazzo — Chairman
- Jess Alston — Board Member (F-Prime Capital)
- Kevin Bitterman — Board Member (Atlas Venture)
- Thomas Cahill — Board Member (Newpath Partners)
- Bihua Chen — Board Member (Cormorant Asset Management)
- Michael A. Kelly — Board Member (Sentry Hill Partners)
- Melissa J. Moore — Board Member (Independent)

## Questions

### Who runs investment decisions at nChroma Bio?

nChroma Bio operates as an operating company, not a fund, so capital allocation and pipeline decisions are made by CEO Jeffrey Walsh and the executive team under board oversight. The board includes representatives from Atlas Venture, F-Prime Capital, Newpath Partners, Cormorant Asset Management, and independent directors including Spark Therapeutics co-founder Jeff Marrazzo (Chair). The firm has not disclosed a separate investment committee structure.

### What is the relationship between nChroma Bio and the former Chroma Medicine / Nvelop Therapeutics?

nChroma Bio was formed by merging the two companies in December 2024. Chroma Medicine contributed the epigenetic editing platform and intellectual property co-invented by Angelo Lombardo and Luigi Naldini. Nvelop Therapeutics contributed in vivo delivery technologies and the executive leadership team, including CEO Jeffrey Walsh and CSO Melissa Bonner. The combined entity operates from a single site in Boston.

### Which editing modalities does nChroma Bio's platform actually cover?

The scientific founders' published work spans CRISPR base editing (David Liu), epigenetic silencing (Angelo Lombardo, Luigi Naldini), zinc-finger nucleases and CRISPR off-target analysis (Keith Joung), and AAV capsid engineering (Aravind Asokan, chair of the scientific advisory board). nChroma states it is targeting in vivo delivery of 'genetic cargoes' — a term broad enough to include editors, suppressors, and writers — but has not publicly specified which modalities are in active development.

### Who are the investors behind nChroma Bio?

The founding syndicate includes Atlas Venture, F-Prime Capital, and Newpath Partners, all of which have board seats, alongside Cormorant Asset Management, whose founder Bihua Chen also sits on the board. nChroma has not disclosed total capital raised or specific deal terms for the merger.

### What is nChroma Bio's relationship to Spark Therapeutics?

There is no corporate relationship. Chairman Jeff Marrazzo co-founded Spark Therapeutics in 2013, led it as CEO until its 2019 sale to Roche for $4.8 billion, and oversaw the first FDA approval of a gene therapy for a genetic disease (LUXTURNA). His board presence gives nChroma access to rare operational experience in gene-therapy commercialization, but the two companies are independent.

## Related profiles

- [NextGen Security](https://altss.com/profile/nextgen-security)
- [Parameter](https://altss.com/profile/parameter)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/nchroma-bio

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology